Premium
Systematic review: epidemiology of hepatitis C genotype 6 and its management
Author(s) -
Chao D. T.,
Abe K.,
Nguyen M. H.
Publication year - 2011
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2011.04714.x
Subject(s) - genotype , medicine , hepatitis c virus , epidemiology , hepatitis c , hepacivirus , ribavirin , pegylated interferon , virology , antiviral therapy , immunology , virus , chronic hepatitis , biology , genetics , gene
Aliment Pharmacol Ther 2011; 34: 286–296 Summary Background Hepatitis C virus (HCV) genotype 6 is common among patients from Southeast Asia and the surrounding regions, where HCV prevalence is also high. HCV genotype 6 has great genetic diversity and different response to antiviral therapy compared with the more commonly known genotype 1. Aim Our goal was to provide a systematic review of the current literature on the epidemiology, classification and treatment of HCV genotype 6. Methods A search using PubMed for ‘hepatitis C’ AND ‘genotype 6’ produced a total of 47 articles, of which 33 articles were found to be relevant and included in this review. Additional articles were identified using the reference lists of these 33 primary articles. Results The prevalence of HCV genotype 6 is estimated to be as high as 50% in some regions of Southeast Asia with demonstrated significance among intravenous drug users and thalassemia major patients. Although previous line probe assays may have misclassified HCV genotype 6 as genotype 1, newer line probe assays can more accurately and reliably determine HCV genotype. Patients infected with HCV genotype 6 respond better to interferon‐based therapy compared with those infected with genotype 1, although patient baseline clinical characteristics and side effect profiles are similar between HCV genotype 6 and other HCV genotypes. Conclusions Future studies should seek to clarify issues regarding early predictors for treatment response in patients with HCV genotype 6, and the impact of ethnic and genotypic factors to treatment response in HCV genotype 6 patients.